ALS caregivers across Canada can now access free professional counseling

I left my husband, Todd, at home in Michigan last week while I flew with our teenage son to Florida during his spring break. Getting away takes planning and requires a lot of help at home while I’m gone. For me to be able to leave, we had to assemble…

Advocates and lawmakers are racing against a looming September deadline to prevent a “funding cliff” for critical amyotrophic lateral sclerosis (ALS) research and treatment access. The ALS Association is now throwing its full weight behind the newly reintroduced ACT for ALS Reauthorization Act (H.R. 8205), a bipartisan push…

Some days, my life with ALS feels like I’m trying to force a square peg into a round hole. On second thought, forget “some days” — I feel that way almost every day. There are the small irritations, such as having to wrestle with uncooperative Velcro on my…

Shionogi has completed its acquisition of global rights to Radicava and Radicava ORS, two edaravone formulations approved to treat amyotrophic lateral sclerosis (ALS), from Tanabe Pharma, finalizing a deal announced late last year. When it signed the agreement, Tanabe said it would establish a U.S.-based company to…

A large-scale genetic analysis has identified several new rare mutations linked to amyotrophic lateral sclerosis (ALS), with findings suggesting that about a quarter of patients have an identifiable genetic contributor to their disease, according to a new study. The results, which come from an analysis of nearly 18,000 people…

People living with amyotrophic lateral sclerosis (ALS) in the U.S. generally prefer care models where they can see multiple healthcare providers during the same visit, rather than only regularly seeing a neurologist who refers them to other doctors as needed, according to a new study. The findings have important…

Up to six people with advanced amyotrophic lateral sclerosis (ALS) will be treated with Trethera’s experimental therapy TRE-515 under a collaboration with Massachusetts General Hospital (MGH). The patients will receive the oral treatment through a U.S. Food and Drug Administration (FDA) expanded access program (EAP), which allows people…

When my husband Todd’s new power wheelchair was delivered, he tried a device that allowed him to control it with his eyes. It included software running on a tablet computer and an eye-tracking system mounted to the front of the chair. He found the system frustrating because he was…

A pivotal Phase 3 clinical trial testing pridopidine, an experimental oral therapy being developed by Prilenia Therapeutics and Ferrer, in people with early, rapidly progressive amyotrophic lateral sclerosis (ALS) has enrolled its first participant. PREVAiLS (NCT07322003), which was cleared late last year by the…